Genmab — Januar 2023
-
Genmab-topchef: Tre kræftmidler er på vej mod væsentlige milepæle i 2023 - https://medwatch.dk/Medicinal___Biotek/article14766808.ece - godt nytår
-
En lille nyhed, som ikke er nævnt fra før nytår. FDA godkender kræftmiddel fra Roche https://medwatch.dk/Medicinal___Biotek/article14761309.ece
-
Eyes have been opened to the Genmab-Biontech collaboration, says CEO
The companies’ partnership is moving into a ”more promising phase,” and investors have begun to pay attention, says Genmab CEO Jan van de Winkel while championing the collaborative approach.
(medwatch.com)
-
Genmab to Present at the 41st Annual J.P. Morgan Healthcare Conference https://www.proinvestor.com/investornyt/922129/genmab-to-present-at-the-41st-annual-jp-morgan-healthcare-conference
-
-
-
Og så kører 1042 jo nu også i flere kombier med kemo, og har en arm med bugspytkirtlen også. https://clinicaltrials.gov/ct2/show/NCT04083599?term=Gen1042&draw=2&rank=1
-
Tirsdagens danske avisuddrag med Vestas, elbiler og kapitalfonde https://www.proinvestor.com/investornyt/922276/tirsdagens-danske-avisuddrag-med-vestas-elbiler-og-kapitalfonde
-
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma https://www.globenewswire.com/news-release/2023/01/03/2581869/0/en/Janssen-Submits-Marketing-Authorisation-Application-to-the-European-Medicines-Agency-Seeking-Approval-of-Talquetamab-for-the-Treatment-of-Patients-with-Relapsed-or-Refractory-Multi.html
-
-
Transactions with shares and linked
securities in Genmab A/S made by managerial employees and their closely associated persons https://www.proinvestor.com/investornyt/922570/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees-and-their-closely-associated-persons -
USA/lukning: Apple og Tesla ødelagde nytårsfesten https://www.proinvestor.com/investornyt/922650/usa-lukning-apple-og-tesla-odelagde-nytarsfesten
-
Genmab A/S (NASDAQ:GMAB - Get Rating) had its target price increased by investment analysts at JPMorgan Chase & Co. from 3,450.00 to 3,600.00 in a research note issued on Tuesday, The Fly reports. The firm currently has an "overweight" rating on the stock. https://www.marketbeat.com/instant-alerts/nasdaq-gmab-a-buy-or-sell-right-now-2023-01/
-
Hummingbird -which previously tried to work with Genmab's Duobody technology- now wants to try Synaffix ADC tech, just like Genmab. Funny that Genmabs deal with Synaffix was also on Jan 4, last year
https://hummingbirdbioscience.com/hummingbird-bioscience-and-synaffix-enter-license-agreement-to-develop-a-next-generation-antibody-drug-conjugate-adc-program/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind